Drugs for Treatment of Diarrhea-Predominant IBS

Alosetron is a 5-HT3 antagonist that blocks serotonin receptors crucial for gut motility, pain, and nausea. By inhibiting these receptors, it reduces bowel contractions and slows colonic stool transit. This allows the intestines to absorb more fluid, effectively reducing diarrhea and easing abdominal pain in IBS-D patients.

Eluxadoline is a mixed opioid-receptor agonist and antagonist that acts locally in the gut to reduce abdominal pain and diarrhea. It affects enteric neurons controlling gut motility and visceral pain sensations. Despite limited oral bioavailability, it effectively slows intestinal transit and improves stool consistency without triggering central nervous system opioid effects.

Alosetron can cause constipation, ischemic colitis, vomiting, and hemorrhoids. Ischemic colitis is particularly serious and led to the drug's initial market withdrawal. Due to these risks, alosetron is now restricted to severe IBS-D cases in women unresponsive to conventional therapies and requires physician certification and patient consent protocols.

Eluxadoline is dosed at 100 mg twice daily with food in patients with a gallbladder and 75 mg twice daily in patients without one. It is contraindicated in patients with biliary duct obstruction, sphincter of Oddi dysfunction, or a history of pancreatitis. These dosing adjustments and restrictions account for the drug's hepatic metabolism and potential pancreatitis risk.

IBS-D is characterized by chronic abdominal pain and diarrhea, requiring dietary modifications, stress management, and targeted drug therapy with agents like alosetron and eluxadoline. Unlike inflammatory bowel diseases, IBS-D treatment focuses on symptom relief rather than addressing underlying inflammation, making pharmacological approaches distinct from drugs for treatment of constipation predominant IBS or other bowel conditions.

Eluxadoline's primary side effects include constipation, nausea, and abdominal pain. Pancreatitis is a notable concern, which is why the drug is prohibited in patients with a history of pancreatic disease. Additionally, there is a potential risk of addiction due to its opioid-receptor activity, though local gut action minimizes systemic effects.

Alosetron requires a prescription program with physician certification and patient consent due to the serious risk of ischemic colitis, which can be fatal. Patients must be educated about warning signs and risks before treatment begins. This restricted distribution model ensures that only qualified healthcare providers prescribe it to appropriate candidates who understand potential complications.